Over 120 California Auctions End Tomorrow 09/17 - Bid Now
Over 2100 Total Lots Up For Auction at Five Locations - UT 09/20, MD 09/22, TX 09/24, FL 09/28, NJ Cleansweep 09/30

KT and NeuroSigma announce strategic digital health partnership

Press releases may be edited for formatting or style | June 15, 2021 Business Affairs
Jun 14, 2021 -- SEOUL, South Korea and LOS ANGELES, June 14, 2021 /PRNewswire/ -- KT Corporation and NeuroSigma, Inc. jointly announced signing of a memorandum of understanding, forming a strategic partnership to develop and commercialize, inside and outside of Korea, electronic therapies treating neurological and neuropsychological disorders, including ADHD, depression, and epilepsy. NeuroSigma is the developer of the Monarch eTNS System®, which uses non-invasive external trigeminal nerve stimulation (eTNS) to treat neurological and neuropsychiatric indications, and is the first device-based, non-drug therapy approved by the FDA to treat pediatric ADHD. In addition, NeuroSigma plans to conduct additional trials for label expansion of the Monarch eTNS System in ADHD and pivotal trials for depression and epilepsy.

Through this partnership with NeuroSigma, KT will support

the design and development of next-generation versions of eTNS products incorporating artificial intelligence (AI), big data, and cloud capabilities;

Servicing GE/Siemens Nuclear Medicine equipment with OEM trained engineers

Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.

advanced monitoring and AI analysis services, provided through KT's digital healthcare platform; and
commercialization and manufacturing partnerships in Korea.
The partnership also contemplates a potential strategic investment by KT in NeuroSigma.

KT, a leading digital platform company, has created a digital healthcare platform, through which it has a significant, growing presence in the healthcare ecosystem. At the end of last year, KT established a new division, the Digital & Bio-Health Organization, residing within KT's Future Value Promotion Office and under direct control of CEO Koo Hyun-mo, to further advance the digital healthcare platform. Through this platform, KT is forming various partnerships with hospitals, pharmaceutical companies, academic associations, and biotech ventures and will oversee its new partnership with NeuroSigma. In addition, earlier this year, the head of the Future Value Promotion Office, Kim Hyung-wook, became chairman of Korea's Digital Health Industry Association.

Kim Hyung-wook, KT's Head of Future Value Promotion Office, said, "In Korea, digital therapy is still in its infancy, but its utility and growth potential are excellent. Starting with our strategic partnership with NeuroSigma, we will actively foster and promote digital therapeutics, including electronic drugs, as the basis of new and innovative healthcare businesses and to expand the digital therapeutics market in Korea and beyond." Mr. Kim added, "We have been impressed with NeuroSigma's eTNS System, which has already shown itself to be a safe and effective alternative to drug-based therapies. We are eager to work with NeuroSigma to integrate this industry-leading digital therapy into our growing digital healthcare platform and to develop the next generations of digital therapy."

You Must Be Logged In To Post A Comment